ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240

AIMS: This post hoc analysis evaluated albumin/bilirubin (ALBI) score, an objective measure of liver function, in patients receiving pembrolizumab plus best supportive care (BSC) compared with placebo plus BSC in the KEYNOTE-240 study. METHODS: Patients with confirmed hepatocellular carcinoma (HCC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogel, Arndt, Merle, Philippe, Verslype, Chris, Finn, Richard S., Zhu, Andrew X., Cheng, Ann-Lii, Chan, Stephen Lam, Yau, Thomas, Ryoo, Baek-Yeol, Knox, Jennifer, Daniele, Bruno, Qin, Shukui, Wei, Ziwen, Miteva, Yanna, Malhotra, Usha, Siegel, Abby B., Kudo, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488519/
https://www.ncbi.nlm.nih.gov/pubmed/34616489
http://dx.doi.org/10.1177/17588359211039928

Ejemplares similares

Ejemplares similares